James Patrick Solomon

James Patrick Solomon

Auto-generated profile, based on publicly available information

James Patrick Solomon

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
TBTejus A. Bale
Tejus A. Bale
SYSoo-Ryum Yang
Soo-Ryum Yang
JSJames P. Solomon
James P. Solomon
KNKhedoudja Nafa
Khedoudja Nafa
SMSumit Middha
Sumit Middha
MAMaria E. Arcila
Maria E. Arcila

31 August 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JSJames P. Solomon
James P. Solomon
SYSoo-Ryum Yang
Soo-Ryum Yang
NCNoura J. Choudhury
Noura J. Choudhury
RPRyan N. Ptashkin
Ryan N. Ptashkin
NENasrin Eslamdoost
Nasrin Eslamdoost
MAMaria E. Arcila
Maria E. Arcila
Purpose: Clinical relevance thresholds and laboratory methods are poorly defined for MET amplification, a targetable biomarker across malignancies. Experimental Design: The utility of next-generation sequencing (NGS) in assessing MET copy number alterations was determined in >50,000 solid tumors. Using fluorescence in situ hybridization as reference, we validated and optimized NGS analysis. Results: Incorporating read-depth and focality analyses achieved 91% concordance, 97% sensitivity, and 89% specificity. Tumor heterogeneity, neoplastic cell proportions, and genomic focality affected MET amplification assessment. NGS methodology showed superiority in capturing overall amplification status in heterogeneous tumors and defining amplification focality among other genomic alterations. MET copy gains and amplifications were found in 408 samples across 23 malignancies. Total MET copy number inversely correlated with amplified segment size. High-level/focal amplification was enriched in certain genomic subgroups and associated with targeted therapy response. Conclusions: Leveraging our integrated bioinformatic approach, targeted therapy benefit was observed across diverse MET amplification contexts.

1 November 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
HPHyeon J. Park
Hyeon J. Park
IBInji Baek
Inji Baek
GCGloria Cheang
Gloria Cheang
JSJames P. Solomon
James P. Solomon
WSWei Song
Wei Song

5 May 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RRRenuka Raman
Renuka Raman
JVJacques A. Villefranc
Jacques A. Villefranc
TUTimothy M. Ullmann
Timothy M. Ullmann
JTJessica Thiesmeyer
Jessica Thiesmeyer
VAViviana Anelli
Viviana Anelli
YHYariv Houvras
Yariv Houvras
Genetic alterations in RET lead to activation of ERK and AKT signaling and are associated with hereditary and sporadic thyroid cancer and lung cancer. Highly selective RET inhibitors have recently entered clinical use after demonstrating efficacy in treating patients with diverse tumor types harboring RET gene rearrangements or activating mutations. In order to understand resistance mechanisms arising after treatment with RET inhibitors, we performed a comprehensive molecular and genomic analysis of a patient with RET-rearranged thyroid cancer. Using a combination of drug screening and proteomic and biochemical profiling, we identified an adaptive resistance to RET inhibitors that reactivates ERK signaling within hours of drug exposure. We found that activation of FGFR signaling is a mechanism of adaptive resistance to RET inhibitors that activates ERK signaling. Combined inhibition of FGFR and RET prevented the development of adaptive resistance to RET inhibitors, reduced cell viability, and decreased tumor growth in cellular and animal models of CCDC6-RET–rearranged thyroid cancer.

22 March 2025 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
ADAlicia Dillard
Alicia Dillard
KXKemin Xu
Kemin Xu
YSYichao Sun
Yichao Sun
HLHan-Hsuan Lin
Han-Hsuan Lin
CSCong Shen
Cong Shen
JSJames P. Solomon
James P. Solomon
Oncogenic fusion detection is an essential part of clinical diagnosis and management of non-small-cell lung carcinoma. Numerous methods are available for detection of oncogenic fusions in the clinical laboratory, although RNA sequencing has rapidly gained prominence. Accordingly, however, multiple different RNA-sequencing assays exist, with diverse methods and varying performance characteristics. Here, a single-institutional clinical experience with a testing algorithm for non-small-cell lung carcinoma that uses amplicon-based DNA/RNA sequencing, followed by reflex hybridization-capture-based RNA sequencing if the initial testing is negative for oncogenic drivers, is reported. A total of 1211 non-small-cell lung carcinoma specimens were received for molecular testing, and 120 (approximately 10%) were reflexed for hybridization-capture-based RNA sequencing. Of the 120 cases tested, oncogenic fusions were identified in 9 and included clinically actionable fusions involving ALK, BRAF, NRG1, NTRK3, ROS1, and RET. None of these fusions was detected by the amplicon-based assay. Review of the 20,900 non-small-cell lung cancer cases in the American Association for Cancer Research Project Genie version 15.1 publicly available database (registration required) revealed that of the 1081 cases harboring fusions, 893 (82.6%) could theoretically be detected by the amplicon-based assay. Overall, this study shows that the addition of reflex hybridization-capture-based RNA sequencing could improve detection of rare and novel oncogenic fusions, maximizing patient eligibility for appropriate targeted therapies or clinical trials.

31 October 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
LCLuchang Cui
Luchang Cui
JLJuhong Lee
Juhong Lee
JMJuliet Miller
Juliet Miller
MTMinmeng Tang
Minmeng Tang
SASajjad Abedian
Sajjad Abedian
YSYiwey Shieh
Yiwey Shieh
Background: The proportion of lung cancers affecting individuals who have never smoked is growing, with these cancers being prone to harbor mutations in the EGFR gene. Little is known about risk factors and prognostic indicators for EGFR-mutant cancers, with current research limited by the scarcity of datasets integrating genomic, clinical, and environmental data. Methods: We created the Meyer Cancer Center Molecularly Enhanced Lung Cancer Database (MCC-MELD), including lung cancer cases from a large catchment area in New York City. We identified cases through linkage to our institution’s cancer registry and a clinician-initiated, manually curated database. We linked all cases to the electronic health record and in-house tumor genomic testing results. We used natural language processing (NLP) to extract unstructured genomic testing results and detailed smoking history. We linked geocoded addresses to detailed area-level measures. Results: MCC-MELD contains 9,573 patients with lung cancer diagnosed from 1988 to 2024, of whom 20% were non-Hispanic Asian, 14% were non-Hispanic Black, and 8% were Hispanic. We identified 1,092 (11.4%) EGFR-mutant cancers, with NLP identifying 397 cases not identified by structured data. NLP showed high accuracy in ascertaining EGFR status (97%) and quantitative smoking history variables (90%–98%). Never smokers made up 16% of the cases in MCC-MELD. Conclusions: MCC-MELD is an NLP-enhanced database containing clinical information, genomic testing results, and linkages to area-level data for patients with lung cancer from a diverse urban setting. Impact: This resource can facilitate studies on lung cancer risk factors, treatment patterns, and outcomes by EGFR and other driver mutation status.